Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Sarcoma Specialty Channel

FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
News
Selinexor Improves PFS, Time to Next Treatment in Metastatic, Advanced Dedifferentiated Liposarcoma
06/02/2022

John Otrompke

John Otrompke
Second-line or later treatment with selinexor for metastatic, advanced dedifferentiated liposarcoma was associated with longer PFS and time to next treatment compared to placebo.
Second-line or later treatment with selinexor for metastatic, advanced dedifferentiated liposarcoma was associated with longer PFS and time to next treatment compared to placebo.
Second-line or later treatment...
06/02/2022
Oncology
Test Your Knowledge
Quiz: Do Randomized Trials With QoL Assessment Achieve A Clinical Benefit?
09/14/2021
True or false: In the treatment of advanced STS, randomized trials with QoL assessment were more likely to achieve the ESMO-Magnitude of Clinical Benefit Scale substantial benefit threshold.
True or false: In the treatment of advanced STS, randomized trials with QoL assessment were more likely to achieve the ESMO-Magnitude of Clinical Benefit Scale substantial benefit threshold.
True or false: In the treatment...
09/14/2021
Oncology
Conference Coverage
Evaluating Magnitude of Clinical Benefit in the GIST, STS Treatment Landscape
09/14/2021
The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.
The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.
The ESMO-MCBS medical device was...
09/14/2021
Oncology
Test Your Knowledge
Quiz: FDA Approves First Treatment Option for Kaposi Sarcoma in How Many Years?
11/09/2020
True or false: The FDA recently approved the first new AIDS-related Kaposi sarcoma treatment in 6 years.
True or false: The FDA recently approved the first new AIDS-related Kaposi sarcoma treatment in 6 years.
True or false: The FDA recently...
11/09/2020
Oncology
News
FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumors
10/26/2020
The FDA has approved the NGS companion diagnostic FoundationOne CDx test to identify NTRK gene fusions in solid tumor tissue from patients eligible for treatment with larotrectinib.
The FDA has approved the NGS companion diagnostic FoundationOne CDx test to identify NTRK gene fusions in solid tumor tissue from patients eligible for treatment with larotrectinib.
The FDA has approved the NGS...
10/26/2020
Oncology
Podcasts
Episode 4: Evolving Therapies for Ewing Sarcoma
10/15/2020
In the fourth episode, Brian Van Tine, MD, PhD, and Robert “Bob” Maki, MD, PhD, discuss recent trial data and evolving therapies for treatment of Ewing sarcoma.
In the fourth episode, Brian Van Tine, MD, PhD, and Robert “Bob” Maki, MD, PhD, discuss recent trial data and evolving therapies for treatment of Ewing sarcoma.
In the fourth episode, Brian Van...
10/15/2020
Oncology
Episode 3: Standard of Care Treatment for Ewing Sarcoma
Podcasts
Episode 3: Standard of Care Treatment for Ewing Sarcoma
09/24/2020
Brian Van Tine, MD, PhD, and Robert “Bob” Maki, MD, PhD, discuss recent data comparing the American Standard versus European Standard for treatment of Ewing sarcoma.
Brian Van Tine, MD, PhD, and Robert “Bob” Maki, MD, PhD, discuss recent data comparing the American Standard versus European Standard for treatment of Ewing sarcoma.
Brian Van Tine, MD, PhD, and...
09/24/2020
Oncology
News
Doxorubicin–Pembrolizumab Combo Shows Promise in Advanced Anthracycline-Naïve Sarcoma
09/23/2020
Doxorubicin combined with pembrolizumab has shown promise in the treatment of patients with advanced anthracycline-naïve sarcoma, according to phase 1/2 study findings.
Doxorubicin combined with pembrolizumab has shown promise in the treatment of patients with advanced anthracycline-naïve sarcoma, according to phase 1/2 study findings.
Doxorubicin combined with...
09/23/2020
Oncology
Test Your Knowledge
Quiz: Which of These Agents Yielded Durable Responses in Patients With Epithelioid Sarcoma?
08/13/2020
In a large clinical study, which of the following agents yielded durable responses in patients with epithelioid sarcoma?
In a large clinical study, which of the following agents yielded durable responses in patients with epithelioid sarcoma?
In a large clinical study, which...
08/13/2020
Oncology
Test Your Knowledge
Quiz: Is Surgical Resection a Primary Therapy Option for TGCT?
08/11/2020
True or False: Radiotherapy is no longer a primary therapy option in most tertiary tumor centers, while surgical resection, either open or arthroscopic, is.
True or False: Radiotherapy is no longer a primary therapy option in most tertiary tumor centers, while surgical resection, either open or arthroscopic, is.
True or False: Radiotherapy is...
08/11/2020
Oncology

Advertisement

News

FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
News
Selinexor Improves PFS, Time to Next Treatment in Metastatic, Advanced Dedifferentiated Liposarcoma
06/02/2022

John Otrompke

John Otrompke
Second-line or later treatment with selinexor for metastatic, advanced dedifferentiated liposarcoma was associated with longer PFS and time to next treatment compared to placebo.
Second-line or later treatment with selinexor for metastatic, advanced dedifferentiated liposarcoma was associated with longer PFS and time to next treatment compared to placebo.
Second-line or later treatment...
06/02/2022
Oncology
Conference Coverage
Evaluating Magnitude of Clinical Benefit in the GIST, STS Treatment Landscape
09/14/2021
The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.
The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.
The ESMO-MCBS medical device was...
09/14/2021
Oncology
News
FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumors
10/26/2020
The FDA has approved the NGS companion diagnostic FoundationOne CDx test to identify NTRK gene fusions in solid tumor tissue from patients eligible for treatment with larotrectinib.
The FDA has approved the NGS companion diagnostic FoundationOne CDx test to identify NTRK gene fusions in solid tumor tissue from patients eligible for treatment with larotrectinib.
The FDA has approved the NGS...
10/26/2020
Oncology
News
Doxorubicin–Pembrolizumab Combo Shows Promise in Advanced Anthracycline-Naïve Sarcoma
09/23/2020
Doxorubicin combined with pembrolizumab has shown promise in the treatment of patients with advanced anthracycline-naïve sarcoma, according to phase 1/2 study findings.
Doxorubicin combined with pembrolizumab has shown promise in the treatment of patients with advanced anthracycline-naïve sarcoma, according to phase 1/2 study findings.
Doxorubicin combined with...
09/23/2020
Oncology
News
Maintenance Cyclophosphamide Plus Celecoxib Feasible for Metastatic Ewing Sarcoma
05/31/2020
A maintenance therapy regimen comprising oral cyclophosphamide plus celecoxib has demonstrated feasibility in patients with metastatic Ewing sarcoma.
A maintenance therapy regimen comprising oral cyclophosphamide plus celecoxib has demonstrated feasibility in patients with metastatic Ewing sarcoma.
A maintenance therapy regimen...
05/31/2020
Oncology
News
FDA Approves Pomalidomide for Certain Adults With Kaposi Sarcoma
05/15/2020
The FDA has approved pomalidomide for use in adults with AIDS-related Kaposi sarcoma unresponsive to antiretroviral therapy and Kaposi sarcoma in HIV-negative adults.
The FDA has approved pomalidomide for use in adults with AIDS-related Kaposi sarcoma unresponsive to antiretroviral therapy and Kaposi sarcoma in HIV-negative adults.
The FDA has approved...
05/15/2020
Oncology
News
High Frequency of Pathogenic Germline Variants Observed in Patients With Osteosarcoma
05/06/2020
Germline genetic testing may be warranted for patients with osteosarcoma, according to findings from a study by Lisa Mirabello, PhD, et al.
Germline genetic testing may be warranted for patients with osteosarcoma, according to findings from a study by Lisa Mirabello, PhD, et al.
Germline genetic testing may be...
05/06/2020
Oncology
News
No OS Benefit in Adding Olaratumab to Doxorubicin for Advanced STS
04/29/2020
Adding olaratumab to doxorubicin in patients with advanced STS did not significantly improve OS in the ANNOUNCE clinical trial.
Adding olaratumab to doxorubicin in patients with advanced STS did not significantly improve OS in the ANNOUNCE clinical trial.
Adding olaratumab to doxorubicin...
04/29/2020
Oncology
News
Ivosidenib Safe, Active in Patients With Advanced Chondrosarcoma
04/13/2020
In a study of patients with chondrosarcoma, ivosidenib therapy yielded limited toxicity and durable disease control.
In a study of patients with chondrosarcoma, ivosidenib therapy yielded limited toxicity and durable disease control.
In a study of patients with...
04/13/2020
Oncology

Interactive Features

Test Your Knowledge
Quiz: Do Randomized Trials With QoL Assessment Achieve A Clinical Benefit?
09/14/2021
True or false: In the treatment of advanced STS, randomized trials with QoL assessment were more likely to achieve the ESMO-Magnitude of Clinical Benefit Scale substantial benefit threshold.
True or false: In the treatment of advanced STS, randomized trials with QoL assessment were more likely to achieve the ESMO-Magnitude of Clinical Benefit Scale substantial benefit threshold.
True or false: In the treatment...
09/14/2021
Oncology
Test Your Knowledge
Quiz: FDA Approves First Treatment Option for Kaposi Sarcoma in How Many Years?
11/09/2020
True or false: The FDA recently approved the first new AIDS-related Kaposi sarcoma treatment in 6 years.
True or false: The FDA recently approved the first new AIDS-related Kaposi sarcoma treatment in 6 years.
True or false: The FDA recently...
11/09/2020
Oncology
Test Your Knowledge
Quiz: Which of These Agents Yielded Durable Responses in Patients With Epithelioid Sarcoma?
08/13/2020
In a large clinical study, which of the following agents yielded durable responses in patients with epithelioid sarcoma?
In a large clinical study, which of the following agents yielded durable responses in patients with epithelioid sarcoma?
In a large clinical study, which...
08/13/2020
Oncology
Test Your Knowledge
Quiz: Is Surgical Resection a Primary Therapy Option for TGCT?
08/11/2020
True or False: Radiotherapy is no longer a primary therapy option in most tertiary tumor centers, while surgical resection, either open or arthroscopic, is.
True or False: Radiotherapy is no longer a primary therapy option in most tertiary tumor centers, while surgical resection, either open or arthroscopic, is.
True or False: Radiotherapy is...
08/11/2020
Oncology
Test Your Knowledge
Quiz: Is Cabozantinib a Potential New Therapy Option for Ewing Sarcoma, Osteosarcoma?
07/20/2020
True or False: Cabozantinib has shown anti-tumor activity in patients with advanced Ewing sarcoma and osteosarcoma.
True or False: Cabozantinib has shown anti-tumor activity in patients with advanced Ewing sarcoma and osteosarcoma.
True or False: Cabozantinib has...
07/20/2020
Oncology
Test Your Knowledge
Quiz: Types of Tenosynovial Giant Cell Tumors
01/10/2020
What are the 2 types of tenosynovial giant cell tumors?
What are the 2 types of tenosynovial giant cell tumors?
What are the 2 types of...
01/10/2020
Oncology
Test Your Knowledge
Quiz: Which Joints Do Tenosynovial Giant Cell Tumors Affect?
01/06/2020
True or False: Almost any joint in the body can be affected by tenosynovial giant cell tumors.
True or False: Almost any joint in the body can be affected by tenosynovial giant cell tumors.
True or False: Almost any joint...
01/06/2020
Oncology
Test Your Knowledge
Quiz: Use of DCC-3014 for Diffuse-Type TGCT
12/18/2019
Findings from a phase 1 trial show that DCC-3014 is ______ in patients with diffuse-type TGCT.
Findings from a phase 1 trial show that DCC-3014 is ______ in patients with diffuse-type TGCT.
Findings from a phase 1 trial...
12/18/2019
Oncology
Test Your Knowledge
Quiz: Traditional Management of TGCT
12/18/2019
True or False: Historically, TGCT has been managed by multiple surgical resections, including joint replacement therapy and (even in rare cases) amputation.
True or False: Historically, TGCT has been managed by multiple surgical resections, including joint replacement therapy and (even in rare cases) amputation.
True or False: Historically,...
12/18/2019
Oncology
Test Your Knowledge
Quiz: Is Pazopanib a Therapy Option for Extraskeletal Myxoid Chondrosarcoma?
10/01/2019
True or False: Pazopanib may be a suitable therapy option for patients with progressive and advanced extraskeletal myxoid chondrosarcoma who do not respond to first-line anthracycline-based chemo.
True or False: Pazopanib may be a suitable therapy option for patients with progressive and advanced extraskeletal myxoid chondrosarcoma who do not respond to first-line anthracycline-based chemo.
True or False: Pazopanib may be...
10/01/2019
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
News
Selinexor Improves PFS, Time to Next Treatment in Metastatic, Advanced Dedifferentiated Liposarcoma
06/02/2022

John Otrompke

John Otrompke
Second-line or later treatment with selinexor for metastatic, advanced dedifferentiated liposarcoma was associated with longer PFS and time to next treatment compared to placebo.
Second-line or later treatment with selinexor for metastatic, advanced dedifferentiated liposarcoma was associated with longer PFS and time to next treatment compared to placebo.
Second-line or later treatment...
06/02/2022
Oncology
Conference Coverage
Evaluating Magnitude of Clinical Benefit in the GIST, STS Treatment Landscape
09/14/2021
The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.
The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.
The ESMO-MCBS medical device was...
09/14/2021
Oncology
News
FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumors
10/26/2020
The FDA has approved the NGS companion diagnostic FoundationOne CDx test to identify NTRK gene fusions in solid tumor tissue from patients eligible for treatment with larotrectinib.
The FDA has approved the NGS companion diagnostic FoundationOne CDx test to identify NTRK gene fusions in solid tumor tissue from patients eligible for treatment with larotrectinib.
The FDA has approved the NGS...
10/26/2020
Oncology
News
Doxorubicin–Pembrolizumab Combo Shows Promise in Advanced Anthracycline-Naïve Sarcoma
09/23/2020
Doxorubicin combined with pembrolizumab has shown promise in the treatment of patients with advanced anthracycline-naïve sarcoma, according to phase 1/2 study findings.
Doxorubicin combined with pembrolizumab has shown promise in the treatment of patients with advanced anthracycline-naïve sarcoma, according to phase 1/2 study findings.
Doxorubicin combined with...
09/23/2020
Oncology
News
Maintenance Cyclophosphamide Plus Celecoxib Feasible for Metastatic Ewing Sarcoma
05/31/2020
A maintenance therapy regimen comprising oral cyclophosphamide plus celecoxib has demonstrated feasibility in patients with metastatic Ewing sarcoma.
A maintenance therapy regimen comprising oral cyclophosphamide plus celecoxib has demonstrated feasibility in patients with metastatic Ewing sarcoma.
A maintenance therapy regimen...
05/31/2020
Oncology
News
FDA Approves Pomalidomide for Certain Adults With Kaposi Sarcoma
05/15/2020
The FDA has approved pomalidomide for use in adults with AIDS-related Kaposi sarcoma unresponsive to antiretroviral therapy and Kaposi sarcoma in HIV-negative adults.
The FDA has approved pomalidomide for use in adults with AIDS-related Kaposi sarcoma unresponsive to antiretroviral therapy and Kaposi sarcoma in HIV-negative adults.
The FDA has approved...
05/15/2020
Oncology
News
High Frequency of Pathogenic Germline Variants Observed in Patients With Osteosarcoma
05/06/2020
Germline genetic testing may be warranted for patients with osteosarcoma, according to findings from a study by Lisa Mirabello, PhD, et al.
Germline genetic testing may be warranted for patients with osteosarcoma, according to findings from a study by Lisa Mirabello, PhD, et al.
Germline genetic testing may be...
05/06/2020
Oncology
News
No OS Benefit in Adding Olaratumab to Doxorubicin for Advanced STS
04/29/2020
Adding olaratumab to doxorubicin in patients with advanced STS did not significantly improve OS in the ANNOUNCE clinical trial.
Adding olaratumab to doxorubicin in patients with advanced STS did not significantly improve OS in the ANNOUNCE clinical trial.
Adding olaratumab to doxorubicin...
04/29/2020
Oncology
News
Ivosidenib Safe, Active in Patients With Advanced Chondrosarcoma
04/13/2020
In a study of patients with chondrosarcoma, ivosidenib therapy yielded limited toxicity and durable disease control.
In a study of patients with chondrosarcoma, ivosidenib therapy yielded limited toxicity and durable disease control.
In a study of patients with...
04/13/2020
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement